



ASX Release

Quarterly Cash Flow Report

Quarter ended 30 June 2016

Melbourne, Australia; 29 July 2016: Jayex Healthcare Limited (ASX: JHL) (**Jayex** or **Company**), a leading e-health provider of integrated healthcare services delivery platforms, today released its Appendix 4C – Quarterly cash flow report for the quarter ended 30 June 2016 (the **Quarter**).

Highlights for the Quarter

- Cash receipts from sales of \$2.96 million for the quarter ending 30 June 2016 and \$6.39 million for the six months to 30 June 2016;
- Cash position for the group of \$1.74 million as at 30 June 2016;
- Successful implementation of the Enlighten platform into a major Melbourne Hospital;
- Commencement of commercial pilot for the P2U prescription delivery service;
- Completion of a number of international proposals, which if successful would significantly increase the Company's footprint and revenue generation; and
- Integration and restructure of subsidiaries post IPO have progressed slower than anticipated but are now well advanced.

The Appendix 4C for the Quarter is set out below. As the Company has adopted a financial year ending on 31 December, "year to date" information is for the 6 months ended 30 June 2016.

The Company expects to release a further detailed update on activities early next week.

ENDS

Contacts for further information:

Executive Chairman
Michael Boyd
0447 600 888

Company Secretary
Melanie Leydin
0417 663 119

About Jayex Healthcare Limited - www.jayexhealthcare.com.au

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service ; and
- the *BluePoint*® remote pharmacy prescription processing and dispensing terminal.

Jayex offers 24/7, online, interconnected 'end-to-end' and 'state-of-the-art' healthcare service delivery platforms for:

- Patients – particularly the "time-poor", the elderly and chronically ill who would likely benefit from better quality and more convenient healthcare services; and
- GPs/Healthcare professionals, clinics, pharmacies and hospitals – particularly those who want to deliver better healthcare services and enhanced patient well-being, more efficiently and at a lower cost, while at the same time, having the potential to increase their productivity, efficiency and profitability.

The Jayex technologies are designed to meet the demands and expectations of patients, GPs, AHPs, clinics, pharmacies and hospitals in today's market, and has the versatility and flexibility to accommodate future demands.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

JAYEX HEALTHCARE LIMITED

ABN

15 119 122 477

Quarter ended ("current quarter")

30 JUNE 2016

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (6 months) \$A'000
1.1 Receipts from customers	2,956	6,387
1.2 Payments for		
(a) staff costs	(1,164)	(2,286)
(b) advertising and marketing	(21)	(81)
(c) research and development	(46)	(129)
(d) leased assets	(26)	(28)
(e) other working capital	(2,782)	(4,986)
1.3 Dividends received		
1.4 Interest and other items of a similar nature received	1	2
1.5 Interest and other costs of finance paid	(3)	(4)
1.6 Income taxes paid		
1.7 Other (provide details if material)		
Net operating cash flows	(1,085)	(1,125)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (6 months) \$A'000
1.8 Net operating cash flows (carried forward)	(1,085)	(1,125)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	(1,062)
(b) equity investments		
(c) intellectual property		
(d) physical non-current assets	-	(3)
(e) other non-current assets		
1.10 Proceeds from disposal of:		
(a) businesses (item 5)		
(b) equity investments		
(c) intellectual property		
(d) physical non-current assets		
(e) other non-current assets		
1.11 Loans to other entities		
1.12 Loans repaid by other entities		
1.13 Other (provide details if material)	(150)	(150)
Net investing cash flows	(150)	(1,215)
1.14 Total operating and investing cash flows	(1,235)	(2,340)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.		
1.16 Payments for capital raising costs	(55)	(362)
1.17 Proceeds from borrowings (convertible notes)		
Proceeds from borrowings (other)		
1.18 Repayment of borrowings – bank loan		
Repayment of borrowings – shareholder loans	-	(5)
1.19 Dividends paid		
1.20 Other (provide details if material)		
Net financing cash flows	(55)	(367)
Net increase (decrease) in cash held	(1,290)	(2,707)
1.21 Cash at beginning of quarter/year to date	3,031	4,637
1.21.a Cash acquired on acquisitions		
1.22 Exchange rate adjustments to item 1.21.a	1	(188)
1.23 Cash at end of quarter	1,742	1,742

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(82)
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Director fee payments for the quarter

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

--

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

--

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash


Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,742	2,731
4.2 Deposits at call	-	300
4.3 Bank overdraft		
4.4 Other (provide details)		
Total: cash at end of quarter (item 1.23)	1,742	3,031

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Jayex Technologies Limited	-
5.2 Place of incorporation or registration	United Kingdom	-
5.3 Consideration for acquisition or disposal	\$9,082,378 Note: Business was acquired in December 2015, final payment of \$1,062,000 paid in January 2016	-
5.4 Total net assets	\$3,195,389 (provisional)	-
5.5 Nature of business	Development and sales of health services workflow hardware and software systems.	-

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.



Sign here:
 (Company secretary)

Date: 29 July 2016

Print name: MELANIE LEYDIN

+ See chapter 19 for defined terms.

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.